AFT PHARMACEUTICALS LIMITED — Director's Dealing 2017

Jun 18, 2017

==> picture [109 x 26] intentionally omitted <==

Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

ToNZX Limited; and		AFT Pharmaceuticals Limited(AFT)19-Jun-1725-May-17John Douglas WilsonAFT Pharmaceuticals Limited(AFT)Not applicableDirector Fully-Paid OrdinaryShares in AFTBeneficial interest as beneficiary of trust.Power to control the exercise of the right to voteas director and shareholder of Gillespie NomineeLimited.50,02256,689Gillespie Nominees Limited as Trustee of theAJJD TrustGillespie Nominees Limited as Trustee of theAJJD Trust116-Jun-17Allotment of new Ordinary Shares pursuant toShare Purchase PlanNot applicableNZ$2.25per share6,667NoNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicable	AFT Pharmaceuticals Limited(AFT)19-Jun-1725-May-17John Douglas WilsonAFT Pharmaceuticals Limited(AFT)Not applicableDirector Fully-Paid OrdinaryShares in AFTBeneficial interest as beneficiary of trust.Power to control the exercise of the right to voteas director and shareholder of Gillespie NomineeLimited.50,02256,689Gillespie Nominees Limited as Trustee of theAJJD TrustGillespie Nominees Limited as Trustee of theAJJD Trust116-Jun-17Allotment of new Ordinary Shares pursuant toShare Purchase PlanNot applicableNZ$2.25per share6,667NoNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicable
Name of listedissuer:
Date this disclosuremade:
Date of last disclosure:
Directororsenior managergiving disclosure
Full name(s):
Name of listedissuer:
Name of related body corporate (ifapplicable):
Position heldin listedissuer:
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)Class ofaffected quotedfinancialproducts:
Class ofaffected quotedfinancialproducts:		Fully-Paid OrdinaryShares in AFT
Nature of the affected relevant interest(s):		Beneficial interest as beneficiary of trust.Power to control the exercise of the right to voteas director and shareholder of Gillespie NomineeLimited.
For that relevant interest-
Number heldinclass before acquisitionordisposal:		50,022
Number heldinclass afteracquisitionordisposal:		56,689
Current registered holder(s):		Gillespie Nominees Limited as Trustee of theAJJD Trust
Registered holder(s) once transfers are registered:		Gillespie Nominees Limited as Trustee of theAJJD Trust
Details of transactions giving rise to acquisition or disposal
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:		1
Date of transaction:
Nature of transaction:
Name of anyotherpartyorparties to the transaction(if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisitionor disposal. If the consideration was not in cash and cannot be readily by converted into acash value,describe the consideration:
Number of financialproducts to which the transaction related:
If the issuer has a financial products trading policy that prohibits directors or seniormanagers from trading during any period without written clearance (a closed period)include thefollowing details—
Whether relevant interests were acquired or disposed of duringa closedperiod:		No
Whether prior written clearance was provided to allow the acquisition or disposal toproceed during the closed period:		Not applicable
Date ofthe prior writtenclearance (ifany):		Not applicable
Summary of other relevant interests after acquisition or disposal:Class ofquoted financialproducts:Nature of relevant interest:_For that relevant interest,- _Number held in class:Current registered holder(s):For a derivative relevant interest,-Type of derivative:Details of derivative,-
		Not applicable
The notional value of the derivative (if any) or the notional amount of underlying financialproducts (ifany):		Not applicable
Astatement as towhetherthe derivativeis cashsettled orphysically settled:		Not applicable
Maturity date ofthe derivative (ifany):		Not applicable
Expiry date ofthe derivative (ifany):		Not applicable
The price's specified terms (ifany):		Not applicable
Any other details needed to understand how the amount of the consideration payableunder the derivative or the value of the derivative is affected by the value of the underlyingfinancialproducts:		Not applicable
_For that derivative relevant interest,- _
Parties to the derivative:		Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevantinterestinthe derivative:		Not applicable

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature: 19-Jun-17

==> picture [490 x 48] intentionally omitted <==